These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27663942)

  • 1. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
    Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
    Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder.
    Lecavalier L; Pan X; Smith T; Handen BL; Arnold LE; Silverman L; Tumuluru RV; Hollway J; Aman MG
    J Autism Dev Disord; 2018 Apr; 48(4):980-987. PubMed ID: 29022125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caregiver Satisfaction with a Multisite Trial of Atomoxetine and Parent Training for Attention-Deficit/Hyperactivity Disorder and Behavioral Noncompliance in Children with Autism Spectrum Disorder.
    Hollway JA; Aman MG; Mendoza-Burcham MI; Silverman L; Arnold LE; Tumuluru R; Handen BL; Lecavalier L; Page K; Sayre P; Smith T
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):807-814. PubMed ID: 26797318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.
    Tumuluru RV; Corbett-Dick P; Aman MG; Smith T; Arnold LE; Pan X; Buchan-Page KA; Brown NV; Ryan MM; Hyman SL; Hellings J; Williams C; Hollway JA; Lecavalier L; Rice RR; McAuliffe-Bellin S; Handen BL
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):708-714. PubMed ID: 28509573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Hollway JA; Mendoza-Burcham M; Andridge R; Aman MG; Handen B; Arnold LE; Lecavalier L; Williams C; Silverman L; Smith T
    J Child Adolesc Psychopharmacol; 2018 Mar; 28(2):130-135. PubMed ID: 29112459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
    Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
    Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
    Upadhyaya H; Kratochvil C; Ghuman J; Camporeale A; Lipsius S; D'Souza D; Tanaka Y
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):799-809. PubMed ID: 25265343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
    Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
    Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.
    Arnold LE; Aman MG; Cook AM; Witwer AN; Hall KL; Thompson S; Ramadan Y
    J Am Acad Child Adolesc Psychiatry; 2006 Oct; 45(10):1196-1205. PubMed ID: 17003665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.